U.S. Markets open in 5 hrs 56 mins

Houston Methodist Selects Tabula Rasa HealthCare’s DoseMe For System-wide Precision Dosing Technology

MOORESTOWN, N.J., June 13, 2019 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc.’s (TRHC) (TRHC), a healthcare technology company advancing the field of medication safety, today announced a multi-year partnership agreement between its precision dosing software subsidiary DoseMe and  Houston Methodist for the system-wide implementation of DoseMe’s proprietary dose optimization software, DoseMeRx®.

“DoseMe’s software is a straight-forward way to implement AUC-based decision making in vancomycin dosing, while at the same time minimizing the number of blood draws needed to inform dose adjustments for challenging patient cohorts,” said William L. Musick, PharmD, BCIDP, Clinical Specialist, Infectious Disease and Residency Program Director at Houston Methodist Hospital.

Houston Methodist healthcare system began using DoseMeRx software last year through an agreement with Houston Methodist Hospital. This new agreement will provide Houston Methodist’s network of pharmacy teams access to DoseMeRx across the system’s seven community hospitals, including Houston Methodist Baytown Hospital, Houston Methodist West Hospital, Houston Methodist Sugar Land Hospital, Houston Methodist Clear Lake Hospital, Houston Methodist Willowbrook Hospital, Houston Methodist The Woodlands Hospital, and Houston Methodist Continuing Care Hospital.

“We are so pleased to partner with Houston Methodist and its network of hospitals,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “Houston Methodist’s decision to expand the use of DoseMeRx is clear recognition, by one of the nation’s leading health systems, that there is a need for best-practice standardization for the management of complex patients. DoseMeRx fulfills that need. The platform enables safer dosing techniques, improving quality and outcomes, while at the same time creating more efficient workflows generating significant savings for our customers like Houston Methodist.” 

"We are honored to expand our partnership with the innovative clinical pharmacy departments within the Houston Methodist system, as they continue to lead the way in clinical excellence and patient care here in the United States," said Charles Cornish, CEO of DoseMe.

About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize performance to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.  Medication risk management is TRHC’s lead offering, and its cloud-based software applications, including EireneRx® and MedWise®, provide solutions for a range of payers, providers and other healthcare organizations.  www.tabularasahealthcare.com.

About DoseMe
DoseMe is a Tabula Rasa HealthCare Company (TRHC) and the first company in the world to develop precision dosing software - DoseMeRx - developed specifically for clinical practice. DoseMe's clinical decision support solutions focus on empowering healthcare providers to optimize dosing of high-risk parenteral medications to streamline operations, reduce adverse drugs events, decrease costs and improve patient outcomes. For more information, visit doseme-rx.com

About Houston Methodist
Houston Methodist is one of the nation’s leading health systems and academic medical centers ranked by U.S. News & World Report as the No. 1 hospital in Texas for patient care. Houston Methodist consists of eight hospitals: Houston Methodist Hospital, its flagship academic hospital in Texas Medical Center, and seven community hospitals throughout the Greater Houston metropolitan area. As a consistently recognized leader in patient-centered clinical care, medical research and education, Houston Methodist is committed to using technology to advance patient care. houstonmethodist.org.

Forward-Looking Statements
This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology.  Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions.  These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release.  Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC,  including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 1, 2019, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website http://ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.

Media Contact
Dianne Semingson
dsemingson@trhc.com
T: (215) 870-0829
Investors
Bob East or Asher Dewhurst
Westwicke Partners
tabularasa@westwicke.com
T: (443) 213-0500